Hankey GJ; Hackett ML; Almeida OP; Flicker L; Mead GE; Dennis MS; Etherton-Beer C; Ford AH; Billot L; Jan S; Lung T; Murray V; Lundström E; Anderson CS; Herbert R; Carter G; Donnan GA; Nguyen HT; Gommans J; Yi Q; Li Q; Bompoint S; Barrett S; Claxton A; O'Dea J; Tang M; Williams C; Peterson S; Drummond C; Hong UH; Le LTM; Ngo TTB; Mai YB; Han HT; Truong NQ; Nguyen HT; Ngo HT; Nguyen TB; Ha OTK; Nguyen TLH; Lindley RI; New P; Lee A; Tran TT; Le LTTM; Kieu TLV; Nguyen SV; Nguyen TAD; Dang TN; Phan HTT; Vo LTN; Nguyen MH; Dang HC; Tran HT; Dam LTC; Ngo TTK; Pham TNT; Pham BN; Dao NTT; Le LTC; Do CM; Huynh HQ; Tran GTK; Le OT; Tran LTK; Duong CD; Kieu DV; Le N; Nguyen HN; Le BV; Nguyen LT; Nguyen LV; Dinh TQ; Vo TV; Bui TN; Hoang UTT; Nguyen HTT; Lam NT; Le KK; Trinh PT; Huynh HQ; Nguyen TTT; Lu HN; Pham TH; Nguyen SH; Le NH; Nguyen GT; Doan BT; Pham SP; Luong DH; Mai HV; Tran TV; Do PT; Le HT; Nguyen CV; Nguyen PD; Mai TD; Dao PV, 2020, 'Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial',
The Lancet Neurology, vol. 19, pp. 651 - 660,
http://dx.doi.org/10.1016/S1474-4422(20)30207-6